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Abstract: In most diagnostic laboratories, targeted next-generation sequencing (NGS) is currently the
default assay for the detection of somatic variants in solid as well as haematological tumours. Independent
of the method, the final outcome is a list of variants that differ from the human genome reference sequence of
which some may relate to the establishment of the tumour in the patient. A critical point towards a uniform
patient management is the assignment of the biological contribution of each variant to the malignancy and
its subsequent clinical impact in a specific malignancy. These so-called biological and clinical classifications
of somatic variants are currently not standardized and are vastly dependent on the subjective analysis
of each laboratory. This subjectivity can thus result in a different classification and subsequent clinical
interpretation of the same variant. Therefore, the ComPerMed panel of Belgian experts in cancer diagnostics
set up a working group with the goal to harmonize the biological classification and clinical interpretation
of somatic variants detected by NGS. This effort resulted in the establishment of a uniform, two-level
classification workflow system that should enable high consistency in diagnosis, prognosis, treatment and
follow-up of cancer patients. Variants are first classified into a tumour-independent biological five class
system and subsequently in a four tier ACMG clinical classification. Here, we describe the ComPerMed
workflow in detail including examples for each step of the pipeline. Moreover, this workflow can be
implemented in variant classification software tools enabling automatic reporting of NGS data, independent
of panel, method or analysis software.
Keywords: cancer; classification; guideline; NGS; variant
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1. Introduction
Over the recent years, most molecular diagnostic laboratories have replaced their single gene assays
for analysing tumour samples for clinically relevant variants to massive parallel sequencing, commonly
called Next-Generation Sequencing (NGS). This technique allows the simultaneous interrogation
of multiple genes in several samples starting from limited amounts of DNA. This major change in
diagnostics has now become time- and cost-efficient due to the improved target enrichment methods
and the reduced cost per sample through the massive sequencing capacity [1].
Cancer development is a very complex process that requires the accumulation of several different
acquired genetic changes, also called variants. These include drivers that are essential for tumour
development, and passengers, which accidently occur [2]. Driver variants in oncogenes are activating
changes mostly generated by missense variants or in-frame insertion/deletions (indels) at very specific
positions called hotspots, or by gene amplifications or fusions resulting in a gain-of-function (GoF) of
at least a function of that gene product, which often is its kinase activity. Driver variants in tumour
suppressor (Ts) genes on the other hand negatively affect the proper function of that protein, resulting in
a diminished or abolished protein activity or level. These variants thus induce a loss-of-function (LoF),
and include nonsense variants, frameshift indels and splice site changes, as well as genomic aberrations
that produce a null allele, such as a (partial) gene deletion. Occasionally, a change-of-function can also
result in a cancer driver. Epigenetic inactivation can occur as well [3] but is not described here.
Although the number of clinically relevant tumour-associated variants is steadily increasing, it is
still too low to justify whole genome or exome sequencing [4]. A targeted screening panel from a dozen
to a few hundred genes is currently sufficient for clinical patient management and allows the detection
of single nucleotide variants (SNV) and indels, but can also find copy number variations (CNV),
tumour mutation burden (TMB), homologous recombination deficiency (HRD) and microsatellite
instability (MSI) [5,6]. Moreover, exon skipping, gene fusions and changes in expression levels can also
be detected when starting preferentially from the RNA of a tumour specimen [7].
Independent of the method, targeted NGS analysis ultimately results in a variant call format
(Vcf) file for each sample containing a list of genomic positions at which a change was observed,
compared to the human reference sequence. This list is then extensively filtered to yield a selected
number of clinically relevant variants. These filtering steps typically depend on the underlying clinical
question and will differ for the detection of somatic variants in a cancer biopsy versus germline
variants in a recessive disease entity. After these filtering steps, the remaining variants then need to be
classified for their tumour-inducing and diagnostic potential before reporting can take place. This
crucial classification step includes (1) the biological classification, i.e., its predicted potential to induce
or stimulate tumorigenesis through an altered protein function, and (2) the tumour type-dependent
clinical interpretation, which relates to the potential to alter the clinical management of the patient. It is
important to emphasize that the biological classification of a variant is independent of the underlying
malignancy, whereas the clinical classification is strongly influenced by the specific pathology in which
the variant is found, as well as by several other clinical data. For germline variants, guidelines have
been described to classify variants in biological classes [8] as well as tier-based clinical interpretation
classes [9–11]. For somatic variants however, only guidelines for the clinical interpretation have
been extensively described [12–14] while those for the biological classification are only touched upon
briefly [15] or described for specific disease conditions [16]. Both classifications are however necessary
to be able to standardize variant calling in a diagnostic setting. Until now, lab-specific and thus different
biological classification systems are being used, which can have a significant impact on the reported
clinical consequence.
In a survey organized by the Belgian MolecularDiagnostic.be working group on the biological
and clinical classification of somatic variants, critical differences in the biological classification were
noticed with the expected impact on the clinical reports of the same patients. Very similar results were
reported by the ACMG working group [12]. Therefore, we set up an expert group to harmonize this
first process and present here the Belgian guidelines that were proposed for the biological classification
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of somatic variants detected by NGS. For clinical interpretation, the four tier-based classes reported by
the ACMG were retained, which are described in detail elsewhere [12].
2. Results
2.1. Expert Panel
All molecular diagnostic laboratories in Belgium were invited to join an expert group with a focus
on the analysis and interpretation of NGS variants in the field of solid and haematological tumours.
A total of 91 experts, mainly consisting of molecular biologists, clinical biologists, oncologists and
haematologists were selected to form the Commission for Personalised Medicine (ComPerMed) expert
panel. Members represent 27 Belgian hospitals of which seven academic hospitals, 19 non-academic
hospitals and one laboratory not associated with a hospital. In addition, members of the national
institute for science and health (Sciensano, Brussels, Belgium) were represented to guide the project.
The major aim of this working group is to install guidelines and workflows for personalized cancer
treatment and optimized patient management (https://www.compermed.be/). One of the goals was to
harmonize the biological classification of somatic variants in Belgium through well-defined workflows
to avoid differences between laboratories. For that, a working group of molecular biology experts
in cancer genomics was installed. The second goal was to streamline the clinical interpretation and
reporting of these biologically classified somatic variants to ameliorate the inter-laboratory concordance
of clinical data. The expert panel gathered the first time in January 2018, with subsequent meetings
every 6 months and multiple intermediate electronic communications. The final document was
obtained in January 2019 and published on the BELAC website in French (https://economie.fgov.be/
sites/default/files/Files/Publications/files/Belac-FR/2--405NGS-FR.pdf) and Dutch (https://economie.
fgov.be/sites/default/files/Files/Publications/files/Belac-NL/2--405NGS-NL.pdf) in July 2019. Note
that these guidelines change to English from page five onwards. The focus was on those genes that
were decided by the ComPerMed panel as required to be screened by NGS in the different tumour
types [17–20]. These genes are listed in Tables 1 and 2.
2.2. Variant Calling and Annotation
Targeted NGS is currently a well-established screening method in many molecular diagnostics
laboratories that perform tumour screening for personalized clinical management. These panels
most commonly include twenty to fifty genes, which make them cost-efficient and bioinformatically
manageable. Moreover, small to medium-sized panels avoid the mass introduction of technical
artefacts due to e.g., sequencing-, alignment- and analysis-related errors. A large number of NGS data
analysis pipelines exist, but all will result in a Vcf file for each sample. In this Vcf file, the chromosome
and genomic position for each variant is provided, as well as the reference and alternative base, the
coverage at that position and its variant allele frequency (VAF). Each variant can be a substitution,
deletion, insertion or duplication of one or more nucleotides compared to the human genome reference
sequence. The Vcf file also includes quality-related parameters to be able to judge the likelihood of
a correct call. Subsequently, these files are used for annotation, i.e., assessing the consequence of
that change at the transcript and protein level, and its associated functional and subsequent clinical
effect. For each variant, the HGVS nomenclature [21] at the transcript and protein level, including the
reference sequence accession number with versioning is provided, e.g., EGFR NM_005228.3: c.2573T>G;
NP_005219.2: p.(Leu858Arg), or TET2 NM_001127208.2: c.419del; NP_001120680.1: p.(Asn140Metfs*5).
Moreover, annotation programs include additional information such as its presence in population
databases (gnomAD, dbSNP, 1000 genomes) and/or disease-associated databases (COSMIC, CIVIC,
ClinVar, etc.) as well as the outcome of functional prediction programs (SIFT, MutationTaster), which
assess the deleterious effect of that variant. Based on all this information, the variants are extensively
filtered to retain only the relevant variants with a potential effect on tumour formation. Filtering
excludes intronic regions, except for the AG/GT splice sites, silent changes, recurrent variants that
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likely are sequencing or homopolymer errors that often occur at VAF <10%, and single nucleotide
polymorphisms (SNPs) present in the healthy population. This last step has to be taken with caution
since some germline variants are known to predispose to cancer. Finally, it is highly recommended to
manually inspect variants in sequence visualization programs such as Integrative Genomic Viewer
(IGV; the Broad Institute, Cambridge, MA, USA) to assess the correctness of the annotation, which is
especially important for flanking or neighbouring variants, and indels. Note however, that the quality
of sequencing and mapping of the reads should always be checked for, to avoid false positives.
This variant annotation forms the basis of the biological classification, i.e., the estimation of the
likeliness that a variant contributes to the development or establishment of tumorigenesis. The expert
panel decided to use the five biological classes of the ACMG and AMP Standards and Guidelines
published by Richards and colleagues [8], even though these guidelines were originally described
for germline variants. These entail the classes Pathogenic, Likely Pathogenic, Variant of Unknown
Significance (VUS), Likely Benign, and Benign. Irrespective of their clinical consequence, all known
driver variants end up in the Pathogenic class (e.g., c.1799T>A; p.(Val600Glu) in BRAF) while variants
with a significant minor allele frequency (MAF) in the population, also known as polymorphisms or
SNP’s, are classified as Benign (e.g., c.215C>G; p.(Pro72Arg) in TP53). However, since the classification
is not that clear for many other variants, the expert panel aimed to develop a biological classification
workflow to streamline and harmonize this currently very subjective process. Variants classified in a
biological category will then be further analysed for their clinical impact.
2.3. Biological Variant Classification Workflow
The proposed ComPerMed workflow for biological classification of somatic variants is illustrated
in Figure 1. We will elaborate below on the reasoning behind each step.
Figure 1. ComPerMed workflow for the biological classification of somatic variants.
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When starting from a Vcf file, the first step of the biological classification workflow is a technical
filtering step to select the high quality variants, usually performed by filtering out the unreliable
changes (Figure 1-Box 1). Filtering should be done against variants generated by technical artefacts
including stutters in repeat sequences, alignment errors and sequencing artefacts. A hallmark of such
erroneous variants is that these are typically found in at least 10% of samples, not including variants in
hotspot or variants previously reported in the literature [22]. These technical artefacts can be panel-
and/or method-specific and thus have to be defined by each laboratory individually. Secondly, only
variants that alter the protein sequence in any way (missense, nonsense, in-frame or frameshift indels
and splice variants) have to be retained. Therefore, all variants located in introns, except for the
AG/GT splice sites, as well as stand-alone synonymous changes are filtered out. Even though some of
these changes might result in an alteration of the protein function, insufficient tools or information is
currently available to assess this impact. The final filtering steps are related to the VAF and the read
depth (coverage) of a variant. The VAF typically is validated down to 5% with at least several hundred
reads at that position, indicating that the variant will be detected with high sensitivity and specificity if
at least, e.g., 25 variant reads are present in a total of 500 reads. Again, both thresholds are lab-specific
and require firm validation. However, these thresholds can be reduced for specific variants that need
to be detected at low frequencies (e.g., BRAF c.1799T>A; p.(Val600Glu) in hairy cell leukaemia) but
an extensive validation is needed here as well. Pathogenic and Likely Pathogenic variants that are
filtered out due to a coverage or VAF below the lab-specific thresholds can, however, be considered for
re-analysis with an alternative method.
Variants that pass the above-mentioned technical filtering steps are then checked for their presence
in the healthy population databases (Figure 1-Box 2). It was agreed by the ComPerMed expert panel
that the gnomAD database, an extension of the Exome Aggregation Consortium (ExAC), was the
most comprehensive and curated data repository containing data from more than 125,000 exomes
and 15,000 genomes. Moreover, gnomAD reports ethnic-based MAFs, which our workflow uses to
assign a variant as (Likely) Benign if the MAF is higher than 0.1% in any of the ethnic populations
in which at least 2000 alleles were analysed, e.g., the variant c.4796C>A; p.(Pro1599His) in ALK has
a MAF Total of 0.02% but the MAF in the African population is 0.25% with an interrogated allele
number of 24,968, thereby assigning it as a Likely Benign variant. We thus relax the conservative
value of 1% that is based on whole population-based data. Variants with an ethnic-based MAF
>0.1% and <1% are classified as “Likely Benign” while those ≥1% as “Benign”. The threshold to
discriminate between both classes can be defined by each laboratory individually as these variants
will not be included in the clinical report. Note that (Likely) Benign variants will typically yield VAFs
close to 100% (homozygous) or around 50% (heterozygous) as these are germline variants. Somatic
variants typically have VAFs <50% due to the heterozygous state and the presence of contaminating
healthy cells in the sample but can also have VAFs close to 50% or even >50% because of genomic
amplifications or loss of the wild-type allele. Importantly, as gnomAD might use alternative gene
transcript ID’s compared to those used by annotation programs, clear-cut polymorphic variants can be
missed. Therefore, gnomAD-negative variants with VAF’s close to 50% and 100% should be checked
in dbSNP (https://www.ncbi.nlm.nih.gov/snp/) as well with critical review of the outcome since dbSNP
might include (Likely) Pathogenic variants that were not yet curated.
The remaining pool of somatic variants then needs to be further classified for their potential
tumour pathogenicity. We first classified these variants for which sufficient evidence exists that the
corresponding amino acid change is a driver in cancer (e.g., EGFR p.(Leu858Arg) or JAK2 p.(Val617Phe)).
For that, a Consensus Pathogenic Variant (CPV) list was established for clinically relevant changes in
solid and myeloid tumours (Tables 1 and 2, respectively).
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Table 1. Consensus Pathogenic Variant (CPV) list of the ComPerMed genes selected for screening in solid tumours.
Gene Transcript ID Hs1 Hs2 Hs3 Hs4 Hs5 Hs6 Hs7 Hs8 Hs9 Hs10 Hs11 Hs12
ALK NM_004304.4 F1174L R1275Q
BRAF NM_004333.5 G469A/E/R/V D594G/M T599-K601if-del/ins V600E/K/M/R K601E
BRCA1 NM_007294.3 all clear LoF variants (nonsense, frameshift, splice site)
BRCA2 NM_000059.3 all clear LoF variants (nonsense, frameshift, splice site)
EGFR NM_005228.4 G719A/C/S ex19if-del/ins ex20 if-ins T790M C797S L858R L861Q
ESR1 NM_000125.3 K303R E380Q V392I S463P V533M V534E P535H L536H/P/Q/R Y537C/N/S D538G
GNAS NM_000516.5 R201C/H
H3F3A NM_002107.4 K28M G35R/W
HRAS NM_005343.3 G12C/D/S/V G13C/D/R/S/V Q61H/K/L/R
IDH1 NM_005896.3 R132C/G/H/L/S
IDH2 NM_002168.3 R140L/Q/W R172K/M/S
KIT NM_000222.2
ex8 ex9 ex11 ex11 ex11 ex11 ex11 ex13 ex13 ex14 ex17 ex17
D419 if-del S501-F504 if-ins K550-V560if-indel W557G/R V559A/D V560D L576P K642E V654A T670I D816H/V/Y N822K
KRAS NM_004985.4 G12A/C/D/F/R/S/V G13C/D/R/S/V A59T Q61H/K/L/R K117N A146T
MET NM_001127500.3 ex14 skipping
NRAS NM_002524.4 G12A/C/D/R/S/V G13C/D/R/S/V A59T Q61H/K/L/R K117N A146T
PDGFRA NM_006206.5 S566_E577 if-del D842V D842_I843if-del V561D
Hs: Hotspot; if-del: inframe deletion; if-ins: inframe insertion; _: denotes the exact positions of that change; -: denotes a region in which the change has to be located; LoF: Loss of Function.
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Table 2. Consensus Pathogenic Variant (CPV) list of the ComPerMed genes selected for screening in
myeloid tumours.
Gene TranscriptID Hs1 Hs2 Hs3 Hs4 Hs5 Hs6
ASXL1 NM_015338.5 none
CALR NM_004343.3 ex9of-del ex9of-ins
CEBPA NM_004364.3 none
CSF3R NM_156039.3 T618I
DNMT3A NM_ 175629.2 R882C/H
EZH2 NM_004456.4 Y646F/H/N/S
FLT3 NM_004119.2 ex14if-dup D835A/E/H/V/Y
IDH1 NM_005896.3 R132C/G/H/L/S
IDH2 NM_002168.3 R140L/Q/W R172K/M/S
JAK2 NM_004972.3 ex12 if-del/if-dup V617F
KIT NM_000222.2 see CPV Solid list
MPL NM_005373.2 S505N W515any ms
NPM1 NM_002520.6 ex11of-ins
RUNX1 NM_001754.4 none
SETBP1 NM_015559.3 D868N G870S
SF3B1 NM_012433.3 E622D R625C/H H662Q K666N/R/T K700E G742D
SRSF2 NM_003016.4 P95H/L/R P95_R102del
TET2 NM_001127208.2 none
TP53 NM_000546.5 R175H Y220C G245S R248Q/W R273C/H R282W
U2AF1 NM_006758.2 S34F/Y Q157P/R
WT1 NM_024426.5 none
Hs: Hotspot; if-del: inframe deletion; if-dup: inframe duplication; of-del: out of frame deletion; of-ins: out of frame
insertion; any ms: any missense variant; none: no consensus pathogenic variants present.
Both CPV lists were edited via a consensus of at least six NGS experts in solid or myeloid
malignancies. Initially, both lists are restricted to the driver variants (hotspots) in those proteins for
which the ComPerMed Test Level 1 and 2A (Figure S1) was applicable [23]. In a later stage, both lists
will be extended with additional genes and variants. Proteins with amino acid variants present in
the CPV lists are thus classified as “Pathogenic” (Figure 1-Box 3). Examples are BRAF p.(Val600Met)
(V600M) and SF3B1 p.(Lys666Asn) (K666N). Of special note is that the conversion of the three letter
amino acid code to the one letter code should be performed correctly in order to check the CPV lists.
Several online tools for this conversion are available and should be consulted in case of doubt. Frequent
erroneous conversions are A for Asp or Asn, G for Glu, and T for Trp. However, this issue will be
solved by the implementation of bioinformatic classification and interpretation software, which is
available from several companies now.
Variants that are absent from the CPV list will, by default, not end up in the ”Pathogenic” class and
need further classification. We discriminated those variants by their functional impact. Variants that
result in a clear loss-of-function (LoF), i.e., frameshift, nonsense or AG/GT splice site variant (Figure 1
Box 4) will most likely result in a weakened or null allele. If the LoF variant is located in a tumour
suppressor (Ts) gene, it is likely to result in haploinsufficiency of that Ts gene, irrespective whether it is
present in the last exon, which is a hallmark for cancer (with some exceptions like RB1). Therefore,
these variants should be classified as “Likely Pathogenic“ (e.g., TET2 c.5609C>G; p.(Ser1870*); TP53
c.445dup; p.(Ser149Phefs*32)). Since the driver status for most LoF variants in Ts genes have not been
demonstrated through functional assays, we choose not to classify these as “Pathogenic“. On the
other hand, if a clear LoF variant is present in an oncogene (e.g., KRAS c.343G>T; p.(Gly115*)), it likely
will not play a key role since oncogenes need to be activated or overexpressed. Consequently, these
variants end up in the “Variants of Unknown Significance (VUS)“ class. Alternatively, non-evident
LoF changes, i.e., missense variants or in-frame indels, in Ts- or oncogenes could result in a partial loss
or activated allele, and therefore, will be re-directed to a Scoring Table (Figure 1-Box 5). This table
will guide each non-evident LoF variant towards a classification as “Likely Pathogenic“ or “VUS“,
based on data available in curated databases or in peer-reviewed publications. We compiled a list of
Ts- and oncogenes based on information in OncoKb (http://oncokb.org/cancerGenes), the TSGene 2.0
list (https://bioinfo.uth.edu/TSGene/), Vogelstein et al. [24], and IntOGen (https://www.intogen.org)
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(Table S1). For the few genes that are reported as Ts gene and oncogene, a selection was made for the
tumour type in which it was requested to be screened for.
The Scoring Table consists of four parameters for which a score between −1 and +2 can be obtained
(Table 3). The total score will define the class of each variant with a total score of ≥2 resulting in a
“Likely Pathogenic“ classification and a score <2 in a “VUS“.
Table 3. Scoring Table for the biological variant classification of non-loss-of-function (LoF) variants.
Parameter Score
+2
Score
+1
Score
+0.5
Score
0
Score
−1
Total # of entries of that particular AA
change at that position in COSMIC
Solid: ≥50 50 > x > 10 / ≤10 /
Hemato: ≥10 10 > x > 5 / ≤5 /
In silico prediction tools SIFT and
MutationTaster / /
Both damaging
and deleterious Other /
Harmful in functional studies (PubMed,
JAX-CKB, MDA, MCG) / / Yes Not reported No
Described in at least one genomic db
(CIVIC, ClinVar, OncoKb, VarSome) / /
As (Likely)
Pathogenic
Not
described/unknown
As (Likely)
Benign
Variants with a score ≥2 will be classified as “Likely Pathogenic“. Variants with a score <2 are classified as “VUS“.
The first parameter of the Scoring Table is the total number of entries of the specific amino acid
change in the Catalogue of Somatic Mutations in Cancer (COSMIC; https://cancer.sanger.ac.uk/cosmic/),
preferably the most recent version. Today, COSMIC harbours 6 million manually curated somatic
coding variants related to human cancers, with a focus on the census of cancer genes [25]. Depending on
the number of entries, a score is assigned to each variant. The threshold per score depends on whether
the variant is detected in a solid or a haematological tumour. Indeed, the number of solid tumour
samples in COSMIC is much higher compared to haematological samples, which produces a bias
towards higher numbers in solid cancer samples. These thresholds were set based on testing of many
different variants. To obtain a score of “+2” the threshold was set at a total of 50 entries for solid (e.g.,
EGFR c.2303G>T; p.(Ser768Ile): 265 entries), and 10 for haematological tumours (e.g., SF3B1 c.2219G>A;
p.(Gly740Glu): 15 entries), irrespective of the tumour type in which the variant was detected. A score of
“0“ was given if the number of entries was below 10 for solid (e.g., KRAS c.169G>A; p.(Asp57Asn): seven
entries), or below five for haematological cancers (e.g., TET2 c.2464A>C; p.(Thr822Pro): two entries)
(Table 3). Intermediate numbers were given the score of “+1” (e.g., BRAF c.1790T>G; p.(Leu597Arg):
35 entries; or SRSF2 c.320C>A; p.(Pro107His): seven entries). Our reasoning for the high weight of this
parameter was that a tumour-related variant is expected in a larger number of samples compared to
variants that occur simply as passengers, with minimal effect on tumour development.
The second parameter relates to the in silico prediction tools SIFT and MutationTaster. SIFT (Sorting
Intolerant From Tolerant) determines if an amino acid substitution is deleterious to protein function
mainly based on protein conservation with homologous sequences and the severity of the amino
acid change (http://sift.bii.a-star.edu.sg/www/SIFT_seq_submit2.html). MutationTaster evaluates
DNA sequence variants for their disease-causing potential using a battery of in silico tests, including
Polyphen, to estimate the impact of the variant on the gene product (http://mutationtaster.org/).
The outcome of both prediction tools is often presented in the annotation files. The score of “+0.5“ is
obtained only if both tools predict a damaging or deleterious effect, thereby restricting its impact on
the total score.
Parameter 3 entails whether the variant has been reported as tumorigenic in functional studies. For
that, we advise to use PubMed (https://www.ncbi.nlm.nih.gov/pubmed), Jax-CBK (https://ckb.jax.org/),
MD Anderson Personalized Cancer Therapy (https://pct.mdanderson.org), and My Cancer Genome
(https://www.mycancergenome.org/) as the databases to check. If a functional relation with cancer has
been reported in any of these databases a score of “+0.5“ is attributed to that variant.
Finally, Parameter 4 looks for a detrimental role described for that variant in CIVIC (https:
//civicdb.org/home), ClinVar (http://www.clinvar.com/), OncoKb (http://oncokb.org/#/), and VarSome
Cancers 2019, 11, 2030 9 of 16
(https://varsome.com/). If present as (Likely) Pathogenic in at least one of these databases in a somatic
framework, again a score of “+0.5“ is added. Of special note is that the search for each variant is
dependent on the interrogated database, performed at the protein level using the three- or one-letter
amino acid code (e.g., Ala316Glu or A316E), or at the DNA level.
After carefully checking the above-mentioned databases the sum of the scores of the four
parameters provides the total score. In principle, if the number of COSMIC entries of a particular
amino acid variant is high (≥50 for solid and ≥10 for myeloid tumours), the scoring table will always
yield the class Likely Pathogenic, irrespective of the outcome of the other parameters. On the other
hand, if the number of entries for a specific variant in COSMIC is low (≤10 for solid and ≤5 for myeloid)
it will always be classified as a VUS since the sum of the other three parameters cannot reach the final
score of two. However, careful analysis of Parameters 2 to 4 is necessary for every variant that enters
the Scoring Table irrespective of the number of entries in COSMIC. Strong evidence for a (Likely)
Pathogenic role might have been reported in one of the databases, which then could overrule a VUS
outcome of the Scoring Table to a higher class. It is expected however that only very few variants will
initially fall into this group, but the future availability of many more functional studies will yield more
“overruling” variants from this proposed Scoring Table, which then might need revision.
For variants in genes not present in the CPV lists we score those also via the Scoring Table
with the addition that they can be classified as Pathogenic if the maximal score of +3.5 is obtained.
The overruling possibility can be applied here as well for variants of solid-proven pathogenicity, which
need to be discussed by the expert panel.
Of special note is that the classification via the Scoring Table can be easily automated through
validated in-house developed or commercial software. Several companies are already developing such
a tool, which can be adapted towards selective workflows including the one proposed here.
2.4. Exceptions to the Workflow
Notably, each workflow comes with exceptions. A small set of genes and specific variants
should not be classified via the general workflow and scoring table, since these will result in an
incorrect classification. Our list with exceptions will need to be regularly updated by the expert panel.
The current exceptions are listed below.
1. The Ts gene TP53 is an exceptional gene because of the plethora of variants detected in many
tumour types affecting almost every position of the p53 protein. Therefore, we advise to use two
dedicated TP53 databases to assess variant pathogenicity. The International Agency for Research in
Cancer (IARC) TP53 database (http://p53.iarc.fr/) compiles various types of information on human
TP53 variations in relation to cancer [26]. The second database, Seshat (http://vps338341.ovh.net/),
can be used for (predicted) functional consequences of protein changes. The tumour-related
outcome is presented in the downloadable Summary report. The consensus class indicated
by both tools will be used for TP53 variant classification. However, in comparison with the
ERIC recommendations [27] that classify the −2, −1 and +1, +2 exon flanking splice variants as
Pathogenic, we mark them as Likely Pathogenic since these variants are actually not different from
frameshift variants that are also classified as Likely Pathogenic by ERIC. Secondly, synonymous
changes that are predicted to affect splicing are classified as Pathogenic by ERIC. Importantly,
synonymous changes in P53 should also be checked for a detrimental functional effect in both
TP53 databases.
2. The BRCA1 and BRCA2 Ts genes are specifically analysed for variants in gynaecological tumours
of the ovary and endometrium, as well as in cancers from breast, pancreas and prostate. In these
cases, clear LoF variants (nonsense, frameshift, splice sites) are always classified as Pathogenic,
instead of Likely Pathogenic if classified via the ComPerMed workflow. Notably, LoF variants
in the last exon as well as all other somatic variants need to be checked for their pathogenicity
in different online databases including ARUP (http://www.arup.utah.edu/database/BRCA/),
Cancers 2019, 11, 2030 10 of 16
InterVar (http://wintervar.wglab.org/), ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), Enigma
(https://brcaexchange.org/) and LOVD (https://databases.lovd.nl/shared/genes).
3. Sequencing stutters of short tandem repeats (STR), including homopolymers, often occur as
sequencing errors that are present in Vcf files at low allele frequencies, typically lower than
5%. However, a true change at an STR site can be discriminated from a stutter if the VAF is
significantly higher than the observed stutter error rate present in most samples. The VAF of each
STR variant thus has to be checked and if higher than a validated lab-specific threshold, it should
be regarded as a true event. This threshold has to be defined by each lab since it can be method or
analysis-specific. Each true STR change has to follow the standard classification workflow. As the
prime example, the frameshift c.1934dup in the Ts gene ASXL1 is often seen as a stutter error in
many NGS workflows at VAFs up to 10% but can be also found as a true variant in AML samples
with VAF’s above the lab-specific threshold, thus classifying it as Likely Pathogenic.
4. Splice site variants should be restricted to the −2, −1 and +1, +2 exon flanking positions, which
harbour the AG/GT consensus splice motif, except for the MET exon 14 and BRCA1 and BRCA2
splice regions that should be analysed more broadly. All splice site variants will be considered
as loss-of-function variants (Likely Pathogenic class) even though it might result in an in-frame
exon(s) deletion because loss of at least one exon will most likely functionally harm the protein
as well.
5. Splice site variants in exon 14 of MET have to be seen as a CPV and thus are biologically classified
as Pathogenic.
6. Out-of-frame indels in exon 9 of CALR, including the typical type I and type II mutations, as well
as out-of-frame insertions in exon 11 of NPM1 should not be treated as frameshift variants but as
Consensus Pathogenic Variants (CPVs). Therefore, they are classified as Pathogenic.
7. Somatic in-frame indels in the bZIP domain of CEBPA should be regarded as Likely Pathogenic.
8. Finally, population-specific very rare benign variants can be distinguished from true somatic
variants by their presence in at least three region-specific samples, with VAFs close to 50%,
irrespective of the tumour content or tumour type. Consultancy of neighbouring NGS labs is
advised and follow-up of such Likely Benign variants is warranted.
All classified variants should be collected in a lab-specific internal database generating a fast
and standardized categorization of previously encountered variants. It also allows statistics on their
frequency and easy follow-up in case of a required class switch. We anticipate comparing the internal
databases of clinical laboratories and to build a common Belgian ComPerMed repository for an
extended national standardization.
2.5. The Clinical Report
The clinical report should be as concise as possible and needs to contain the information required
by ISO 15189 for accreditation of medical laboratories. Lengthy reports of more than five pages are
discouraged. The content of the clinical report is described in more detail in the BELAC documents
point 4.11.4 Clinical report at page 22 (https://economie.fgov.be/sites/default/files/Files/Publications/
files/Belac-NL/2--405NGS-NL.pdf). It should include at minimum the order number, name of the
patient, laboratory and physician. The medical information should contain the primary tumour type
and histology as well as the clinical information and specific request, if any. Table 4 lists the required
information that was agreed upon by the expert panel, including examples for each. In addition to the
sample ID, several sample-specific parameters need to be provided as well.
The section ‘Test results’ should include the gene symbol (e.g., EGFR), the variant according to the
HGVS nomenclature at coding (c)DNA (e.g., c.2573T>G) and protein (e.g., p.(Leu858Arg)) level, as
well as the VAF. Though the use of the three letter amino acid code is obliged, the one letter annotation
(e.g., L858R) can be added since this shorter form is generally more familiar to clinicians. The genomic
position of each variant should not be included. Instead, the NM reference number (NCBI) with
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version (e.g., EGFR NM_005228.5) has to be available in the lab guide or on the report at least for
each reported gene. VUS classified variants must be clearly separated from the Pathogenic and Likely
Pathogenic variants and preferably are added at the end of the report or as annex. We recommend to
add a disclaimer for any VUS so that misinterpretation is excluded. In any case, it is imperative that
oncologists/haematologists clearly understand the meaning of these VUS changes. Benign and Likely
Benign variants must not be reported. Importantly, the “Test results” section should also indicate
which regions/exons/genes could not be interpreted or analysed due to biological or technical reasons,
to inform the clinician of any failed amplicons.
Table 4. Sample information required on the report.
Parameter Example(s)
Sample ID (primary lab) 123-45678
Sampling date 16th January 2019
Date of sample received 17th January 2019
Sample tumoral stage primary, metastasis
Sample anatomic site colon, liver, blood, lymph node, . . .
Sample type resection, (trephine) biopsy, aspirate, . . .
Sample procedure FFPE, fresh frozen, fresh tissue, . . .
Neoplastic cells (%) 30%, na
Sample quality disclaimer if sample does not fulfill pre-analytical requirements
na: not applicable.
In the next section ”Conclusion and interpretation” the clinical interpretation of each Pathogenic
and Likely Pathogenic variant together with its clinical tier level needs to be provided. For every
biologically classified variant a clinical class needs to be attributed. We propose to use the four-tiered
ACMG/AMP guideline system described by Li and colleagues [12], which is regarded as the standard
for clinical classification. These four classes are: Tier I (level A and B evidence) for variants of strong
clinical significance in the tumour type investigated; Tier II (level C and D evidence) for variants of
potential clinical significance; Tier III for variants of unknown clinical significance; and finally, Tier
IV for Benign or Likely Benign variants. The clinical classes Tier I, II and III can harbour biologically
classified Pathogenic or Likely Pathogenic variants, which all should be included in the clinical report.
A VUS is always Tier III while Tier IV only contains (Likely) Benign variants. The clinical Tier III, in
case of a VUS, as well as Tier IV class should not be reported in the ‘Conclusion and interpretation’
section. Clinical trials can be included here as well.
The clinical description of Tier I, II and III variants always need to be seen in relation to the
tumour type it was detected in, and should be substantiated by firm publications and up-to-date
clinical databases. Moreover, the clinical impact of each variant, i.e., its diagnostic and prognostic
value, and its sensitivity or resistance to therapy, has to be added in sufficient detail with inclusion of
unequivocal referencing (e.g., Brown et al. 2015; J. Mol. Diagn. or PMID: 31138260). In case of absence
of a variant in a gene that confers resistance to therapy, it is also important that this absence is clearly
mentioned, e.g., no KRAS variant in colorectal adenocarcinoma. However, this section should be as
concise as possible not to overload the physician with superfluous or irrelevant information.
Clinical classification of variants is often not straightforward and is, to a variable extent, amenable
to subjective interpretation. A common point of discussion is how to make the difference between
Level B evidence from well-powered studies (Tier I) and Level C evidence from multiple small studies
(Tier II). Second, how to interpret prognostic markers in haematological malignancies e.g., Likely
Pathogenic variants in ASXL1, TET2, DNMT3A, RUNX1. How to define ‘sufficient evidence’ to rank
them all as Tier I? Finally, combinations of variants might also affect the clinical outcome. These include
resistance variants, which are detected with or without an activating variant. For instance, EGFR
c.2239_2240delinsCC; p.(Leu747Pro) confers resistance to TKI treatment in patients with an activated
EGFR pathway [28,29] and based on the Scoring Table it is classified as Likely Pathogenic. However,
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the clinical interpretation is highly dependent on the co-occurrence of an activating EGFR variant (Tier
I) or not (Tier III). Double variants in CEBPA is another prime example in this category [30,31].
The section ‘NGS method’ should describe in sufficient detail the method, including the type of
sequencer, the targeted genes and their regions or hotspots of the panel (e.g., BRAF: exons 11 and
15; DNMT3A: all coding exons), the reference genome used (e.g., Hg19), the validated coverage (e.g.,
>500×) and VAF (e.g., >5%) thresholds, and all regions or hotspots that consistently fail in the assay
(e.g., DNMT3A: exon 6 AA165–184; JAK2: K539). Moreover, a disclaimer has to be added that the test
cannot discriminate between somatic and germline variants. Note that the method section can also be
consulted in more detail in the versioned lab guide.
Finally, the report should name the person(s) who interpreted and validated the clinical report as
well as the date the report was validated, in agreement with the ISO 15189 norm.
3. Discussion
Several studies already proposed guidelines for the clinical interpretation of somatic variants
in cancer, which is a key step in the process towards efficient clinical patient management [9–14,32],
of which some were critically compared [11,33]. However, this clinical interpretation vastly relies
on the preceding biological variant classification, i.e., is the biological and/or biochemical evidence
sufficiently high to claim that the variant effectively contributes to tumour formation, independent of
the tumour type. Even though every diagnostic laboratory performs this critical step, not a single paper
reports on a detailed somatic variant classification pipeline and proposes a workflow for improved
harmonization. However, several groups describe their classification pipeline for germline variants in
inherited diseases, including cancer [34–39], which are all based on the ACMG guidelines reported
in 2015 [8] and 2017 [12]. For the biological classification of somatic variants the Houston Methodist
Variant Viewer (HMVV) provides easy access to the required biological information of each variant
but does not per se harmonize its final outcome [40]. Very recently, the Spanish guidelines for the
interpretation of NGS variants in myelodysplastic syndrome and chronic myelomonocytic leukaemia
has been reported by GESMD [16].
The expert panel of ComPerMed was installed with the aim to streamline the complete process
from variant detection up to reporting. We decided to use the five biological classes proposed by the
ACMG too, even though these were meant for germline variants [8], i.e., Pathogenic, Likely Pathogenic,
VUS, Likely Benign, and Benign. To uniformly classify variants in either one of these biological classes,
a consensus ComPerMed workflow was installed (Figure 1). From the Vcf files, we first filtered out
the technical errors and common population variants. Then, we checked the variants in the CPV lists,
which included the mutational hotspots of the selected ComPerMed genes to be minimally analysed in
solid and myeloid tumours. If present, these were scored as Pathogenic. From the remaining variants,
the clear LoF variants were classified based on their presence in a Ts gene (Likely Pathogenic) or
oncogene (VUS). Even though nonsense-mediated mRNA decay (NMD) is often not induced when
the LoF variant is located in the last exon, the ComPerMed panel decided to classify those variants
in Ts genes also as Likely Pathogenic because the impact of NMD on cancer genes with premature
stop codons is complex and therefore, currently unpredictable [41]. Moreover, a pathogenic effect of
such an event has been proven for Ts genes including ASXL1, BRCA1 and BRCA2. Finally, a potential
dominant-negative effect of the mutant protein can inhibit the function of the wild-type allele product
thereby stimulating haploinsufficiency. The non-evident LoF variants were subjected to the four
parameter Scoring Table in order to discriminate them between the classes Likely Pathogenic and VUS.
All parameters need to be assessed for every variant as new strong evidence-based information can
still overrule the outcome of this pipeline. Notably, a list of exceptions to the pipeline was compiled to
adjust for an inaccurate outcome of some gene-specific variants.
The guidelines for biological classification we propose here differ from those described by
ACMG [12] and GESMD [16] at some critical points:
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(1) The minor allele frequency (MAF) threshold to assign a variant as a polymorphism (class Likely
Benign or Benign) was set at 1% by ACMG and GESMD, which is especially important in the
absence of paired normal tissue. We have lowered this threshold to 0.1% because of the much
higher number of data since 2015, and the curation of population databases thereby minimising
the contamination of somatic tumour variants. Moreover, this threshold is valid for ethnic-specific
MAFs with at least 2000 alleles investigated [42], which can be consulted in gnomAD. Note
however, that this MAF threshold can be influenced by the targeted NGS method employed [43].
Finally, variants in ASXL1, DNMT3A and TET2 with VAFs below 10% can be associated with
Clonal Hematopoiesis of Indeterminate Potential (CHIP) [44] and thus should be interpreted with
caution as their presence alone is no evidence for the presence of malignancy;
(2) ACMG advises to use the genomic coordinates of variants to be able to query genomic databases
and not to depend on transcripts that are prone to changes. We recommend to use the HGVS
nomenclature with reference to the transcript ID with the NCBI accession number of the main
transcript, with version (e.g., BRAF NM_004333.5). We anticipate to change to the Locus Reference
Genomic (LRG) record (http://www.lrg-sequence.org/) as it contains a stable reference sequence.
So far, not all genes acquired an LRG number, and since most annotation programs and databases
do not yet include the LRG transcript numbers, we did not make this switch yet;
(3) For splice variants, we only consider the intronic −2, −1 (AG) and +1, +2 (GT) consensus splice
positions, except MET exon 14 and BRACA1/2. ACMG and GESMD also evaluates intronic and
exonic variants in the proximity of the splice sites, which are subjected to in-silico splice prediction
tools. However, because of the low specificity of these tools and the inherent requirement for
functional confirmation, we are not in favour of this option;
(4) We classify the LoF variants in the last exon in the same way as those in preceding exons. GESPD
requires the further evaluation of these changes.
This ComPerMed workflow is mainly generated with the aim to be as objective as possible.
For that, the indicated threshold values of all steps need to be rigorously applied. If a variant has
an ethnic-specific MAF of 0.08, it cannot be classified as (Likely) Benign as the MAF is lower than
0.1%. However, if detected in the lab in at least three samples at VAF close to 50% it can still obtain the
(Likely) Benign class, which thus can differ between labs. Also, the exact amino acid change and not a
similar one has to be searched for in the CPV list and indicated databases. It is therefore crucial to make
the correct conversion from the three letter to the one letter amino acid code as different databases
require the input of either of both. For genes not yet present in the CPV list, the lab can add the hotspot
positions of that gene taking into account strict selection criteria for each variant. The cancer hotspot
database https://www.cancerhotspots.org/#/home can be of use as a good starting point [45]. Finally,
the lab-specific coverage and VAF thresholds should be strictly applied. However, for some variants
these thresholds can be relaxed if sufficiently validated. For example, a type I CALR 52 bp deletion
variant with coverage below the threshold can be considered as a correct call. Similarly, detection of a
BRAF V600E in hairy cell leukaemia often requires a VAF below the general threshold of the panel.
Thorough validation of that position can make this detection possible. In general, critical interpretation
of each step of the pipeline is always required since it is expected that some variants won’t fit our
standard pipeline. Any deviation needs to be sufficiently motivated and discussed by the ComPerMed
expert panel.
4. Conclusions
We provide for the first time a detailed workflow for the biological classification of somatic variants
in solid as well as haematological tumours. This workflow was generated in order to harmonize the
reporting of targeted NGS variants in diagnostic laboratories in Belgium under ISO 15189 accreditation.
However, it can also be implemented in other countries or serve as a scaffold for implementation.
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In any case, it will foster discussions on this so far neglected topic, which will be used to improve the
workflow in its future versions.
Supplementary Materials: The following are available at http://www.mdpi.com/2072-6694/11/12/2030/s1, Table S1:
Classification of the most commonly mutated cancer genes as Tumor suppressor gene (TsG) or Oncogene based on 4
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diagnostic/prognostic or therapeutic biomarkers and molecular tests, according to the Belgian healthcare system.
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